Celgene Archives -

Bristol-Myers Squibb’s blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into

BMS’ cash cow Revlimid faces first generic rivals in US

https://pharmaphorum.com/news/bms-cash-cow-revlimid-faces-first-generic-rivals-in-us/

News/ News/ Oncology

BMS finally gets FDA OK for liso-cel, sets $410k launch price

Phil Taylor Breyanzi, Bristol-Myers Squibb, Celgene, cell therapy, DLBCL, immuno-oncology, liso-cel, non-Hodgkin lymphoma, Oncology, TG Therapeutics, Ukoniq 0 Comment

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US

BMS finally gets FDA OK for liso-cel, sets $410k launch price

https://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/

Market Access/ News/ News

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

Phil Taylor Bristol-Myers Squib, Cancer Drugs Fund, Celgene, Haematology, multiple myeloma, NHS, NICE, Oncology, Revlimid, UK 0 Comment

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

https://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/

News/ News/ R&D

BMS/Celgene merger payout evaporates as CVR deadline passes

Phil Taylor Bristol-Myers Squibb, Celgene, Financial, M&A 0 Comment

Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three

BMS/Celgene merger payout evaporates as CVR deadline passes

https://pharmaphorum.com/news/bms-celgene-merger-payout-evaporates-as-cvr-deadline-passes/

News/ News/ Sales and Marketing/ Top stories

Fresh doubts over BMS’ merger payout as FDA delays key drug review

Richard Staines Bristol-Myers Squibb, cancer, Celgene, Sanofi 0 Comment

Holders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out

Fresh doubts over BMS’ merger payout as FDA delays key drug review

https://pharmaphorum.com/news/fresh-doubts-over-bms-merger-payout-as-fda-delays-key-drug-review/

News/ News/ Sales and Marketing

Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?

Phil Taylor Bristol-Myers Squibb, Celgene, fda, liso-cel, manufacturing 0 Comment

Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor

Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?

https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/

News/ News/ Oncology

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

Phil Taylor Bristol-Myers Squibb, CAR T, Celgene, cell therapy, immuno-oncology, Oncology, regulatory 0 Comment

The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel,

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

https://pharmaphorum.com/news/fdas-review-date-for-bms-ide-cel-sneaks-under-the-cvr-wire/

Market Access/ News/ News/ News/ Oncology

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

Phil Taylor Bristol-Myers Squibb, Celgene, Financial, investors, Mergers and acquisitions 0 Comment

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

https://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/

News/ News/ Oncology

Concerns over BMS and Celgene merger payout as FDA extends drug review

Richard Staines blood cancer, Bristol-Myers Squibb, cancer, CAR T, Celgene, liso-cel 0 Comment

Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be

Concerns over BMS and Celgene merger payout as FDA extends drug review

https://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/

Trending

Celgene

Login